Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.

ABSTRACT:

Purpose of review

Rituximab-based chemoimmunotherapy has resulted in a marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). We reflect upon the history front-line (1L) therapy and highlight advances in management.

Recent findings

Since the introduction of R-CHOP, the majority of randomized studies in the front-line treatment of DLBCL have failed to show a benefit. Such studies have involved treatment intensification, adding novel agents to the R-CHOP backbone and targeting such novel agents to biologically defined subgroups. R-CHOP therefore remains standard-of-care for most but new insights into the molecular biology of these diseases, and the development of active targeted molecules offers promise for the future. Accumulating evidence in the very el

SUBMITTER: Kesavan M 

PROVIDER: S-EPMC6647877 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature